Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

TFF1 antibody (C-Term)

This anti-TFF1 antibody is a Mouse Monoclonal antibody detecting TFF1 in IF, FACS and IHC (p). Suitable for Human and Monkey.
Catalog No. ABIN3025060

Quick Overview for TFF1 antibody (C-Term) (ABIN3025060)

Target

See all TFF1 Antibodies
TFF1 (Trefoil Factor 1 (TFF1))

Reactivity

  • 88
  • 17
  • 17
  • 13
  • 11
Human, Monkey

Host

  • 53
  • 47
Mouse

Clonality

  • 51
  • 49
Monoclonal

Conjugate

  • 64
  • 7
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
This TFF1 antibody is un-conjugated

Application

  • 61
  • 46
  • 35
  • 29
  • 19
  • 18
  • 14
  • 8
  • 6
  • 6
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone

TFF1-1091
  • Binding Specificity

    • 29
    • 16
    • 6
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term

    Characteristics

    It recognizes a polypeptide of 6.5 kDa, identified as pS2 estrogen-regulated protein. Its epitope is located in the c-terminus of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

    Purification

    Protein G affinity chromatography

    Immunogen

    A C-terminus peptide was used as the immunogen for the TFF1 antibody.

    Isotype

    IgG1 kappa
  • Application Notes

    Optimal dilution of the TFF1 antibody should be determined by the researcher.

    1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
    2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

    Restrictions

    For Research Use only
  • Concentration

    0.2 mg/mL

    Buffer

    0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store the TFF1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
  • Target

    TFF1 (Trefoil Factor 1 (TFF1))

    Alternative Name

    TFF1

    Background

    It recognizes a polypeptide of 6.5  kDa, identified as pS2 estrogen-regulated protein. Its epitope is located in the c-terminus of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

    Pathways

    EGFR Signaling Pathway
You are here:
Chat with us!